Lauren A. Dalvin - research works

Ocular OncologyCohort studyPrognosisQ2IF 1.3

Only 4% of eyes retained useful vision (≥20/200) 30 years after plaque radiotherapy.

Thirty-year visual acuity outcomes after plaque brachytherapy for posterior uveal melanoma.

Lauren A Dalvin, Gustav Stålhammar
Canadian journal of ophthalmology · May 2026 · Q2 in Ophthalmology
Ocular OncologyAI / informaticsPrognosisQ1IF 3.3

Magnetic Resonance Imaging radiomics model predicted choroidal invasion in intraocular retinoblastoma with AUROC 0.86.

Radiomics to predict high risk features in intraocular retinoblastoma.

Aparna Ramasubramanian … Ron Korn
Eye (London, England) · Jan 2026 · Q1 in Ophthalmology
Ocular OncologyCohort studyPrognosisQ2IF 1.7

Longer delay to treatment linked to higher odds of orbital exenteration in sebaceous carcinoma

Treatment Delay and Risk of Orbital Exenteration in Periocular Sebaceous Carcinoma.

Grant M Welk … Andrea A Tooley
Ocular oncology and pathology · Jun 2026
Ocular OncologyCohort studyTreatmentQ2IF 1.6

Reduced-dose iodine-125 brachytherapy gave 0% local tumor recurrence at 5 years.

Low dose iodine-125 brachytherapy and transpupillary thermal therapy for small- to medium-sized choroidal melanoma.

S Fattahi … K S Corbin
Brachytherapy · Mar 2026
Ocular OncologyObservationalPrognosisQ2IF 1.7

Retinal pigment epithelium undulations on OCT linked to 4-fold higher odds of partial regression

Retinal Pigment Epithelium Undulations in Primary Vitreoretinal Lymphoma: An Under-Recognised OCT Biomarker.

Khushboo Chauhan … Vishal Raval
Ocular immunology and inflammation · Oct 2025 · Q2 in Ophthalmology
ScholarDeck.
Add your own research
Create your profile